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Klotho and the Aging Process
Makoto Kuro-o
Department of Pathology, The University of Texas Southwestern Medical Center, Dallas, TX, USA 
The klotho gene was originally identified as a putative age-suppressing gene in mice that extends life span when 
overexpressed. It induces complex phenotypes resembling human premature aging syndromes when disrupted. The gene 
was named after a Greek goddess Klotho who spun the thread of life. Since then, various functional aspects of the klotho 
gene have been investigated, leading to the identification of multiple novel endocrine axes that regulate various metabolic 
processes and an unexpected link between mineral metabolism and aging. The purposes of this review were to overview 
recent progress on Klotho research and to discuss a novel aging mechanism. (Korean J Intern Med 2011;26:113-122)
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INTRODUCTION
The klotho gene encodes a single-pass transmembrane 
protein and is expressed primarily in the kidney [1]. A 
defect in Klotho expression in mice leads to a syndrome 
resembling aging [1], whereas overexpression of Klotho in 
mice extends life span [2]. The Klotho protein is composed 
of a large extracellular domain (- 130 kD), a transmembrane 
domain, and a very short intracellular domain (10 amino 
acids). The extracellular domain has homology to family 1 
glycosidases (enzymes that hydrolyze terminal glycosidic 
linkages in sugars, glycoproteins, and glycolipids) and is 
subject to ectodomain shedding. As a result, the entire 
extracellular domain is released into the extracellular 
space and is detectable in blood, urine, and cerebrospinal 
fluid [2-5]. Thus, the Klotho protein exists  in two forms: 
membrane Klotho and secreted Klotho (Fig. 1). Mem-
brane Klotho functions as a receptor for a hormone that 
regulates excretion of phosphate and synthesis of active 
vitamin D in the kidney [6-8]. Secreted Klotho functions 
as a humoral factor with pleiotropic activities, including 
suppression of growth factor signaling, suppression of 
oxidative stress, and regulation of ion channels and trans-
porters [9-12].
Function of membrane Klotho
The function of membrane Klotho was not clear un-
til we realized that Klotho-deficient mice and FGF23-
deficient mice suffered identical phenotypes. FGF23 was 
originally described as one of the 22 members of the 
fibroblast growth factor (FGF) family [13]. The function 
of FGF23 became clear when FGF23 was identified as the 
gene mutated in patients with autosomal dominant hypo-
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Figure 1. Membrane Klotho and secreted Klotho. Membrane 
Klotho forms a complex with the fibroblast growth factor  re-
ceptor (FGFR) to create a de novo high-affinity binding site for 
FGF23. Membrane Klotho is subject to ectodomain shedding by 
α- and β-secretases to release secreted Klotho.114    The Korean Journal of Internal Medicine Vol. 26, No. 2, June 2011
phosphatemic rickets (ADHR) [14]: ADHR is character-
ized by hypophosphatemia due to phosphate wasting into 
urine, inappropriately low serum levels of active vitamin 
D (1,25-dihydroxy vitamin D3 or calcitriol), and a defect in 
bone mineralization (rickets). ADHR patients carry mis-
sense mutations in the FGF23 gene, which confer resis-
tance to proteolytic inactivation of FGF23 [15]. As a result, 
serum FGF23 levels are elevated in patients with ADHR. 
Thus, gain-of-function mutations in the FGF23 gene lead 
to phosphate wasting, hypophosphatemia, and rickets. 
These symptoms can be explained by the fact that FGF23 
is a bone-derived hormone that acts on the kidney to in-
crease phosphate excretion into urine (phosphaturia) and 
to suppress calcitriol synthesis [16]. 
In contrast, FGF23-deficient mice suffer phosphate 
retention phenotypes, including hyperphosphatemia and 
vascular calcification [17]. However, in addition to these 
expected phenotypes, FGF23-deficient mice unexpectedly 
develop complex phenotypes resembling aging, including 
growth arrest, kyphosis, osteopenia, emphysematous 
lung, and atrophy of the gonads, thymus, muscle, skin, and 
intestine, which are reminiscent of Klotho-deficient mice 
[18]. Conversely, in addition to aging-like phenotypes, 
Klotho-deficient mice exhibit hyperphosphatemia and 
vascular calcification similar to FGF23-deficient mice 
[1,19,20]. These observations led us to hypothesize that 
Klotho and FGF23 might function in a common signal 
transduction pathway. 
We found that FGF23 requires membrane Klotho 
to bind to cognate FGF receptors [6], which was later 
confirmed independently by other laboratories [7,21]. 
Although FGF23 belongs to the FGF family, it cannot bind 
to the FGF receptor (FGFR) with high affinity. Instead, 
FGF23 uses the Klotho-FGFR complex as its high-affinity 
receptor: Klotho forms a constitutive binary complex 
with FGFR1c, FGFR3c, or FGFR4, thereby creating a de 
novo high-affinity binding site for FGF23 [22]. In other 
words, Klotho functions as an obligate co-receptor for 
FGF23. This explains why mice lacking FGF23 (hormone) 
and Klotho (receptor) develop identical phenotypes. 
Furthermore, kidney-specific expression of Klotho 
explains why FGF23 identifies the kidney as its target 
organ among many other tissues that express multiple 
FGFR isoforms. The Klotho-FGF23 system may represent 
a novel mechanism by which a redundant ligand-receptor 
system secures tissue specificity. 
Endocrine regulation of phosphate homeostasis
Phosphate homeostasis is maintained by a counterbalance 
between absorption of dietary phosphate from the 
intestine and excretion of blood phosphate from the kidney 
into urine [23]. These processes are coordinately regulated 
by several endocrine factors. Calcitriol and parathyroid 
hormone (PTH), which have been extensively studied 
as hormones that regulate calcium metabolism, are also 
involved in phosphate metabolism [24,25]. Calcitriol 
is secreted by the kidney and acts on the intestine to 
increase absorption of calcium and phosphate, thereby 
inducing a positive phosphate balance. PTH is secreted 
from the parathyroid glands in response to decreases in 
serum calcium levels and acts on the kidney to promote 
calcitriol synthesis. However, unlike calcitriol, PTH does 
not induce a net positive phosphate balance, because PTH 
promotes phosphate excretion into urine at the same time. 
Calcitriol in turn suppresses PTH secretion and closes a 
negative feedback loop. Thus, it had been thought until 
quite recently that phosphate metabolism was regulated 
indirectly by calcium-regulating hormones (calcitriol and 
PTH). 
Discovery of the FGF23-Klotho endocrine system has 
transformed this classic view. One critical feature of 
FGF23 is that it requires Klotho to be expressed in target 
organs [11]. FGF23 is secreted from bone and acts on 
the kidney where Klotho is expressed. FGF23 promotes 
phosphate excretion and suppresses calcitriol synthesis in 
the kidney, thereby inducing a negative phosphate balance 
[16]. Klotho is also expressed in parathyroid glands [26], 
indicating that parathyroid is another target organ of 
FGF23. In fact, FGF23 suppresses PTH production and 
secretion [26], further enhancing its ability to suppress 
calcitriol synthesis in the kidney. Expression of the 
FGF23 gene is transactivated with calcitriol in a vitamin 
D receptor dependent manner [27], forming a negative 
feedback loop between bone and kidney. Furthermore, 
PTH increases FGF23 expression [28,29], forming another 
negative feedback loop between bone and the parathyroid. 
These newly identified bone-kidney-parathyroid endocrine 
axes mediated by FGF23 and Klotho add new dimensions 
to the classic view of endocrine regulation of phosphate 
homeostasis (Fig. 2, modified from [30,31]). 
Phosphate and aging
FGF23 functions as a phosphaturic hormone and a 
counter-regulatory hormone for vitamin D (calcitriol) 
in a Klotho-dependent manner. Thus, underlying Kuro-o M. Klotho and the aging process    115
abnormalities caused by defects in the FGF23-Klotho 
system are hyperphosphatemia and hypervitaminosis 
D, suggesting that the complex aging-like phenotypes 
observed in mice lacking FGF23 or Klotho may be 
attributed to phosphate retention and/or vitamin D 
intoxication. Several laboratories have successfully 
rescued the aging-like phenotypes in FGF23-deficient 
mice and/or Klotho-deficient mice by resolving the 
hyperphosphatemia and/or hypervitaminosis D by 
means of dietary and genetic interventions (Table 1, 
modified from [31]). A vitamin D-deficient diet rescued 
many aging-like phenotypes of Klotho-deficient mice [19] 
and FGF23-deficient mice [32]. Similarly, disruption of 
the vitamin D receptor (VDR) gene [33] or the Cyp27b1 
gene (encoding 1a-hydroxylase, an enzyme essential for 
calcitriol synthesis) [18,34] rescues these mutant mice 
as well, implying that excess vitamin D activity might 
be responsible for the aging-like phenotypes. However, 
these dietary and genetic interventions lowered not only 
calcitriol but also phosphate and calcium in the blood, 
raising the possibility that phosphate and/or calcium 
might be the true culprit (s). In fact, a low phosphate diet 
reduces blood phosphate levels and rescues mice lacking 
Klotho [35] or FGF23 [32], despite the observation that it 
did not reduce blood calcium or calcitriol levels. Similarly, 
limiting phosphate reabsorption by deleting the kidney-
specific sodium-phosphate co-transporter type-2a (Npt2a) 
gene reduces blood phosphate levels and rescues these 
mice without restoring serum calcium and calcitriol 
levels to normal [36]. Thus, it is not calcitriol or calcium 
but phosphate that is primarily responsible for the aging-
like phenotypes caused by defects in the FGF23-Klotho 
system. These observations indicate that phosphate 
retention leads to pathologies resembling aging, which 
may be collectively referred to as “phosphatopathies.”
Aging and chronic kidney disease
Phosphatopathies are universally observed in patients 
with chronic kidney disease (CKD). CKD is defined as a 
state of progressive decline of renal function over months/
years caused by any chronic diseases that affect the kidney 
(most notably hypertension and diabetes) and/or natural 
aging. More than 26 million Americans, or 13% of the total 
population, have CKD, which is increasingly recognized as 
a public health problem in the aging society [37,38]. Since 
hyperphosphatemia was identified as a potent mortality 
risk in CKD patients [39-41], lowering blood phosphate 
levels below 4.5 mg/dL with a low phosphate diet and 
phosphate binders (medications that chelate phosphate in 
the gut and prevent its absorption) has been an important 
therapeutic goal in the management of patients with CKD 
[42].
Patients with CKD exhibit a marked decrease in renal 
Klotho expression associated with resistance to FGF23, 
Table 1. Changes in serum levels of Pi, Ca, and vitamin 
D by various interventions that rescue Klotho- and/or 
fibroblast growth factor 23 (FGF23)-deficient mice 
Interventions 
Serum levels
Pi Ca
Vitamin 
D
Low Pi diet ↓ ↑ ↑
Npt2a knockout ↓ ↑ ↑
Cyp27b1 knockout ↓ ↓ ↓
VDR knockout ↓ ↓ ↑
Vitamin D-deficient diet ↓ ↓ ↓
Na-dependent Pi co-transporter type-IIa (Npt2a) is primarily re-
sponsible for renal Pi reabsorption. Thus, loss of Npt2a causes 
Pi wasting into urine and compensatory increases in vitamin D, 
which increases intestinal absorption of both Pi and Ca. Cyp27b1 
encodes 1α-hydroxylase, an enzyme that synthesizes calcitriol 
(active vitamin D). VDR, vitamin D receptor (modified from 
[30,31]).
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Figure 2. Endocrine regulation of phosphate homeostasis 
(modified from [30,31]). Parathyroid hormone (PTH) increases 
synthesis of calcitriol (1,25-dihydroxyvitamin D3) in the kidney 
(a). Calcitriol in turn decreases PTH (b), thereby closing a nega-
tive feedback loop. The fibroblast growth factor 23 (FGF23)-
Klotho system has emerged as the principal phosphate-regu-
lating endocrine axes. FGF23 is secreted from bone and acts 
on kidney to reduce calcitriol synthesis (c). Because calcitriol 
increases FGF23 expression in bone (d), a negative feedback 
loop exists between FGF23 and calcitriol. FGF23 also acts on the 
parathyroid to reduce PTH (e). Because PTH increases FGF23 
expression (f), another negative feedback loop exists between 
PTH and FGF23.116    The Korean Journal of Internal Medicine Vol. 26, No. 2, June 2011
hyperphosphatemia, and vascular calcification, which are 
reminiscent of Klotho-deficient mice [43-45]. Notably, the 
vast majority of patients with CKD die prematurely not 
due to renal failure, but due to early onset of common age-
related diseases such as cardiovascular disease, cancer, 
and infection [46,47]. Consequently, the spectrum of 
death causes in patients with CKD is similar to that of the 
general population. Patients with CKD also suffer many 
aging-like symptoms, including hypogonadism, skin 
atrophy, osteopenia, and cognitive impairment. Thus, 
CKD may be viewed as a state of accelerated aging and/or 
an age-related disease associated with Klotho deficiency 
and phosphate retention. 
Phosphate metabolism in CKD
As functional nephrons are progressively lost during 
the progression of CKD, each nephron is required to 
excrete an increasing amount of phosphate to prevent 
phosphate retention. This can be achieved by increasing 
serum levels of FGF23. However, FGF23 suppresses 
calcitriol synthesis in the kidney at the same time. 
Decreases in functional nephrons capable of calcitriol 
synthesis may also contribute to decreases in calcitriol. 
In fact, increases in FGF23 and decreases in calcitriol 
precede overt hyperphosphatemia during the progression 
of CKD [41]. These observations indicate that early-stage 
patients with CKD maintain normal blood phosphate 
levels by increasing FGF23 to compensate for the reduced 
ability of the kidney to excrete phosphate at the expense 
of calcitriol. Because calcitriol is a potent upregulator 
of Klotho [19], decreases in calcitriol can reduce Klotho 
expression. In fact, decreases in urine Klotho levels 
are observed in the early-stage of CKD long before 
hyperphosphatemia ensues [48]. Because calcitriol also 
functions as a potent suppressor of PTH [24], decreases 
in calcitriol can increase PTH. In fact, serum PTH levels 
start increasing during the early-stage of CKD prior to 
the start of the increase in serum phosphate levels [41]. 
Decreases in Klotho can induce FGF23 resistance in the 
kidney and parathyroid. Moreover, increases in PTH can 
increase FGF23 [29]. Thus, these changes in phosphate-
regulating hormones and Klotho form a vicious cycle, 
leading to high FGF23, high PTH, low calcitriol, and low 
Klotho in patients with end-stage renal disease (Fig. 3, 
modified from [30,31]). Hyperphosphatemia ensues when 
the number of functional nephrons decreases to a level 
that fails to excrete ingested phosphate into urine.
Notably, phosphatopathies such as vascular calci-
fication can occur in patients with CKD and normal 
blood phosphate levels, which is associated with an 
increased incidence of cardiovascular events [46,49,50]. 
One possible explanation for this dissociation would 
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Figure 3. Changes in the phosphate-regulating endocrine system during progression of chronic kidney disease (CKD) (modified from 
[30,31]). (A) Vicious cycles leading to high fibroblast growth factor 23 (FGF23), high parathyroid hormone (PTH), low vitamin D, and 
low Klotho in CKD. (B) Increases in serum FGF23 and serum PTH levels and decreases in serum vitamin D and urine Klotho levels pre-
cede hyperphosphatemia during CKD progression from stage 1 to stage 5.
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be that these patients might suffer postprandial 
hyperphosphatemia, which may be sufficient to induce 
phosphatopathies even if they are normophoshatemic 
under fasting conditions. Because dietary phosphate 
overload can increase blood phosphate levels transiently, 
even in healthy individuals [51], it is possible that patients 
with CKD and a reduced ability to excrete phosphate into 
urine may suffer prolonged and/or enhanced postprandial 
hyperphosphatemia. Another possible explanation would 
be that tissue phosphate content might be increased in 
patients with CKD even if their serum phosphate levels 
are normal. Secreted Klotho protein has activity that 
suppresses phosphate uptake in various types of cells, 
including vascular smooth muscle cells, by inhibiting type-
III sodium-dependent phosphate co-transporters, which 
may protect arteries from calcification [48]. Decreased 
Klotho expression in the kidney of patients with CKD 
potentially reduces blood levels of secreted Klotho and 
promotes vascular calcification. 
Function of secreted Klotho
Membrane Klotho is clipped on the cell surface by mem-
brane-anchored proteases (α- and β-secretases), resulting 
in the secretion of the entire extracellular domain (- 130 
kD) into systemic circulation [3-5]. Secreted Klotho has 
pleiotropic functions as a humoral factor independently of 
FGF23 (Table 2). 
Secreted Klotho belongs to family 1 glycosideses and 
has weak glycosidase activity in vitro [52]. However, 
endogenous substrates for secreted Klotho were not clear 
until the mechanism by which secreted Klotho activates 
the TRPV5 calcium channel was revealed [53,54]. TRPV5 
is expressed on the luminal side of distal tubules in the 
kidney and functions as the rate-limiting entry gate for 
transepithelial calcium reabsorption [55]. TRPV5 activity 
depends on the number of channels present on the cell 
surface, which is regulated by the rate of endocytosis. 
Secreted Klotho suppresses TRPV5 endocytosis by 
modifying its N-linked glycans and increasing the cell-
surface abundance of TRPV5; secreted Klotho removes 
terminal sialic acids in the N-glycan of TRPV5 on the cell 
surface through its putative sialidase activity. Removal of 
terminal sialic acids by secreted Klotho exposes underlying 
galactose residues in the N-glycan, which are ligands for 
a ubiquitous galactose-binding lectin called galectin-1. 
Binding of the modified N-glycan to the galectin-1 lattice 
in the extracellular matrix suppresses TRPV5 endocytosis, 
leading to the accumulation of TRPV5 on the cell surface 
[54]. The  ROMK1 potassium channel is also activated by 
secreted Klotho through the same mechanism [56].
The putative sialidase activity of secreted Klotho 
may also be involved in its ability to suppress kidney-
specific sodium-dependent phosphate co-transporter 
type-IIa (Npt2a) [57]. Npt2a is expressed on the brush 
border membrane of renal proximal tubular cells and 
functions as the major entry gate for transepithelial 
phosphate reabsorption. Modification of the N-glycan 
of Npt2a by secreted Klotho leads to inactivation and 
proteolytic degradation of Npt2a through a mechanism 
yet to be identified. Secreted Klotho also suppresses 
type-III sodium-dependent phosphate co-transporters 
(Pit-1 and Pit-2), which are ubiquitously expressed to 
mediate cellular phosphate uptake [48]. It is possible that 
the ability of secreted Klotho to suppress these sodium-
dependent phosphate co-transporters may contribute to 
preventing phosphatopathies. 
Secreted Klotho regulates the activity of multiple 
growth factors, including insulin/insulin-like growth 
factor-1 (IGF-1) [2], Wnt [58], and transforming growth 
factor (TGF)-β1 [59]. Because adequate suppression of 
insulin/IGF-1 signaling pathway has been identified as an 
evolutionarily conserved mechanism for extending life 
Table 2. Pleiotropic functions of secreted Klotho protein 
Glycoproteins regulated by secreted Klotho Klotho effects 
Ion channels Transient receptor potential vanilloid type isoform-5 (TRPV5) Increase in Ca
2+ influx [54]
Transporters Renal outer medullary potassium channel-1 (ROMK1) Increase in K
+ efflux [56]
Na-dependent phosphate co-transporter, type-IIa (Npt2a) Decrease in Pi influx [57]
Pit-1, 2 (Na-dependent phosphate co-transporter, type-III) Decrease in Pi influx [48]
Receptors Insulin/insulin-like growth factor (IGF)-1 receptors Inhibition [2]
Transforming growth factor (TGF)-β1 receptor (type-II) Inhibition [59]
Secreted Klotho has emerged as a humoral regulator of multiple glycoproteins on the cell surface.118    The Korean Journal of Internal Medicine Vol. 26, No. 2, June 2011
span [60], the anti-aging properties of Klotho may stem 
partly from its ability to suppress insulin/IGF-1 signaling. 
In fact, transgenic mice that overexpress Klotho are long-
lived and slightly resistant to insulin and IGF-1 without 
overt diabetes [2]. The mechanism by which secreted 
Klotho suppresses insulin/IGF-1 signaling remains to 
be determined. However, secreted Klotho inhibits Wnt 
signaling by directly binding to Wnt ligands and preventing 
them from binding to their receptors. Wnt signaling 
is enhanced in Klotho-deficient mice, which results in 
exhaustion of stem cells in highly proliferative tissues such 
as skin and intestine and may partly contribute to atrophy 
of these tissues in Klotho-deficient mice [58]. 
We recently found that secreted Klotho suppresses 
TGF-β1 signaling; secreted Klotho directly binds to type-II 
TGF-β receptor (TGFβR2) on the cell surface and prevents 
TGF-β1 binding to TGFβR2 [59]. TGF-β1 is the most potent 
inducer of the epithelial-to-mesenchymal transition 
(EMT) [61]. EMT is a cellular process whereby epithelial 
cells lose epithelial characters and undergo a phenotypic 
transition to acquire mesenchymal characters, including 
the ability to migrate and proliferate. EMT is essential for 
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Figure 4. Feedback regulation of activity and expression of endocrine fibroblast growth factor (FGFs). (A) The bone-kidney endocrine 
axis (modified from [69]). The active form of vitamin D (calcitriol or 1,25-dihydroxyvitamin D3) binds to vitamin D receptor (VDR). 
The ligand-bound VDR forms a heterodimer with retinoid X receptor (RXR) and functions as a transcription factor that increases 
FGF23 expression in osteocytes. Secreted FGF23 activates FGFR1c, 3c and/or 4 bound by Klotho in renal tubular cells, and suppresses 
CYP27B1 gene expression, which encodes an enzyme that synthesizes calcitriol. Additionally, FGF23 increases expression of the CYP24 
gene, which encodes an enzyme that hydrolyzes and inactivates calcitriol. Thus, FGF23 reduces serum calcitriol levels. (B) The intestine-
liver endocrine axis. Feeding increases the release of bile acids that bind to farnesoid X receptor (FXR). The ligand-bound FXR forms a 
heterodimer with RXR and functions as a transcription factor that increases expression of FGF19 in intestinal epithelial cells. Secreted 
FGF19 activates FGFR4 bound by βKlotho in hepatocytes and suppresses expression of the CYP7A1 gene, which encodes the rate-
limiting enzyme for bile acid synthesis. Thus, FGF19 reduces bile acid synthesis in the liver. (C) The liver-white adipose tissue (WAT) en-
docrine axis. Fasting increases the release of fatty acids that bind to peroxisome proliferator-activated receptor α (PPARα). The ligand-
bound PPARα forms a heterodimer with RXR and functions as a transcription factor that increases expression of FGF21 in hepatocytes. 
Secreted FGF21 activates FGFR1c bound by βKlotho in adipocytes and promotes lipolysis. A CYP gene (s) regulated by the FGF21-
βKlotho system in adipocytes remains to be identified. 
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tissue repair in response to injury but can result in fibrosis 
under pathological conditions in the kidney as well as in 
many other tissues, including the liver, lung, and heart 
[62]. Furthermore, cancer cells undergo EMT and acquire 
the ability to migrate and proliferate, leading to metastasis 
[62]. Thus, the ability of secreted Klotho to inhibit TGF-β1 
activity may counteract EMT and prevent tissue fibrosis 
and cancer metastasis. In fact, injecting secreted Klotho 
prevents renal fibrosis induced by unilateral ureteral 
obstruction and metastasis of human cancer xenografts 
in mice [59]. These activities of secreted Klotho may also 
contribute to life span extension by Klotho overexpression 
in mice [2]. 
The Klotho family and endocrine FGFs
After the discovery of the klotho gene, two Klotho-
related genes were identified based on sequence similarity 
and designated as βKlotho [63] and gKlotho (also known 
as KLPH or LCTL) [64]. The original Klotho has been 
referred to αKlotho when necessary to distinguish it from 
βKlotho and gKlotho. Similar to αKlotho, βKlotho and 
gKlotho are single-pass transmembrane proteins that 
form complexes with FGF receptors [65-67]. βKlotho is 
expressed in various tissues, most notably in the liver and 
white adipose tissue, and forms complexes with FGFR1c 
and FGFR4 [66-68]. gKlotho is expressed in eyes and 
forms complexes with FGFR1b, FGFR1c, FGFR2c, and 
FGFR4 [67]. Importantly, these Klotho-FGFR complexes 
function as high-affinity receptor for endocrine FGFs 
other than FGF23. A phylogenetic analysis has segregated 
FGF23 and two additional FGFs (FGF19 and FGF21) from 
the other FGF family members. These three FGFs, FGF19, 
FGF21, and FGF23, are collectively called endocrine FGFs, 
because they function as hormones, unlike the other FGFs 
that function primarily as paracrine/autocrine factors [69]. 
One critical feature of endocrine FGFs is that they require 
Klothos to be expressed in their target tissues and exert 
their biological activity. FGF19 requires βKlotho [66] or 
gKlotho [67], whereas FGF21 requires βKlotho [65].
FGF19 is secreted from the intestine upon feeding 
and acts on the liver to suppress bile acid synthesis by 
downregulating Cyp7a1 gene expression, which encodes 
the bile acid synthesis rate-limiting enzyme [70]. This 
intestine-liver endocrine axis mediated by FGF19 and 
βKlotho is indispensable for maintaining bile acid 
homeostasis, because mice lacking either FGF15 (the 
mouse ortholog of human FGF19), βKlotho, or FGFR4 (the 
prominent FGFR isoform expressed in the liver) exhibit 
increased Cyp7a1 expression and bile acid synthesis in the 
liver [70-72]. Bile acids bind to the FXR nuclear receptor 
and transactivate the FGF19 gene in the intestine, forming 
a negative feedback loop between the intestine and liver 
[70] (Fig. 4, modified from [69]).
In contrast to FGF19, FGF21 is secreted from the 
liver upon fasting and acts on white adipose tissue to 
induce lipolysis and the metabolic adaptation to fasting 
[73]. Fatty acids bind to the PPARα nuclear receptor 
and transactivate the FGF21 gene in the liver, forming a 
negative feedback loop between white adipose tissue and 
liver. Of note, transgenic mice that overexpress FGF21 
are subject to torpor, a short-term hibernation-like state 
whereby animals reduce activity and body temperature 
to limit energy expenditure [73]. These mice are smaller 
than wild-type mice due to resistance to growth hormone 
and low serum IGF-1 levels [74], suggesting that FGF21 
may extend life span by suppressing the somatotroph-
endocrine axis. 
These observations indicate that the most important 
function of the Klotho family (αKlotho, βKlotho, and gK-
lotho) is to regulate the function of endocrine FGFs (FGF19, 
FGF21, and FGF23) [69]. These newly identified endocrine 
axes mediated by endocrine FGFs and Klothos regulate 
various metabolic processes and have a common negative 
feedback structure composed of lipophilic ligands (bile 
acid, fatty acid, and vitamin D), nuclear receptors (FXR, 
PPARα, and VDR), and cytochrome P450 superfamily 
enzymes (Cyp7a1 and Cyp27b1) (Fig. 4).
CONCLUSIONS
Since the discovery of the klotho gene in 1997 [1], we have 
witnessed several breakthroughs that have significantly 
advanced our understanding of Klotho protein function. 
Membrane Klotho functions as the obligate co-receptor 
for FGF23, a bone-derived phosphaturic hormone. Defects 
in either FGF23 or Klotho result in phosphate retention 
associated with complex aging-like phenotypes, which we 
propose calling phosphatopathies. These findings have 
revealed an unexpected link between phosphate and aging 
[75]. Phosphate retention associated with Klotho deficiency 
is universally observed in patients with CKD, suggesting 
that CKD may be viewed as a state of accelerated aging. 
Discovery of the Klotho family members have identified 
multiple novel endocrine axes and opened a novel research 
field in endocrinology. Further studies on the Klotho 120    The Korean Journal of Internal Medicine Vol. 26, No. 2, June 2011
family are expected to provide new insights into endocrine 
regulation of various metabolic and aging processes.
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